Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cellular viscous properties in senescence: An emerging biophysical perspective and potential biomarker.

Ageing research reviews·2026

Same author

Prediction of low birth weight using machine learning-based analysis of environmental and maternal risk factors: insights from the Korean CHildren's ENvironmental health study (Ko-CHENS).

Environmental research·2026

Same author

Paraben mixture exposure and liver function in pregnant women: Findings from the Korean CHildren's ENvironmental health Study (Ko-CHENS).

Environmental pollution (Barking, Essex : 1987)·2026

Same author

Holotomography-based, label-free quantification of cellular dry mass as a biophysical indicator of microglial Aβ phagocytosis during senescence.

Biogerontology·2026

Same author

New legal category of 'advanced regenerative medicine treatment' in Korea's amended regenerative medicine law: comparative lessons from Japan.

Stem cell reports·2026

Same author

Holotomography-Based, Label-Free Quantification of Cellular Dry Mass as a Biophysical Indicator of Microglial Aβ Phagocytosis during Senescence.

Research square·2026

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

CYP2C19 polymorphism in Korean patients on warfarin therapy.

Sukhyang Lee¹, Hyun Jin Hwang, Jae-Moon Kim

¹Graduate School of Clinical Pharmacy, Sookmyung Women's University, Seoul 140-742, Korea.

Archives of Pharmacal Research

|April 12, 2007

Summary

CYP2C19 genetic variations influence warfarin dosage and bleeding risks in Koreans. Higher CYP2C19 allele frequency correlates with increased bleeding complications, impacting warfarin therapy management.

Related Experiment Videos

Last Updated: Jul 15, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

Pharmacogenomics
Clinical Pharmacology

Background:

Warfarin dosing is complex, influenced by genetic factors.
CYP2C19 enzyme activity affects warfarin metabolism.
Understanding genetic variations is crucial for personalized medicine.

Purpose of the Study:

To investigate the impact of CYP2C19 polymorphism on warfarin dosage.
To assess the relationship between CYP2C19 variants and bleeding complications in Koreans.
To compare CYP2C19 polymorphism distribution in Asian versus Caucasian populations.

Main Methods:

Patient stratification into four groups based on warfarin dose and bleeding.
Genotyping for CYP2C19*2 and CYP2C19*3 using restriction fragment length polymorphism.
Analysis of International Normalized Ratio (INR) and administered warfarin dosage.

Main Results:

Significant differences in administered warfarin dosage were observed despite similar INR.
CYP2C19*2 showed higher genetic variation than CYP2C19*3 in Korean patients.
A higher allele frequency of CYP2C19 was associated with increased bleeding complications.
CYP2C19 polymorphism distribution in Asians is more similar to other Asian populations than to Caucasians.

Conclusions:

CYP2C19 genetic variations are critical determinants of warfarin response and bleeding risk in the Korean population.
Personalized warfarin therapy considering CYP2C19 genotype is recommended.
Further research into pharmacogenomic variations across diverse populations is warranted.